Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSStandard

RELEUKO

FILGRASTIM-AYOW

Standard Dose
480MCG/0.8ML
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Prescription
Summary

Approval overview RELEUKO is listed in Drugs@FDA under application 761082 (BLA).

Marketing status: Prescription Active ingredient FILGRASTIM-AYOW Form and strength SOLUTION;SUBCUTANEOUS - 480MCG/0.8ML Sponsor KASHIV BIOSCIENCES LLC Submission history Latest submission status date: 2025-04-29 00:00:00.

Structured Monograph

Clinical summary

Approval overview RELEUKO is listed in Drugs@FDA under application 761082 (BLA). Marketing status: Prescription Active ingredient FILGRASTIM-AYOW Form and strength SOLUTION;SUBCUTANEOUS - 480MCG/0.8ML Sponsor KASHIV BIOSCIENCES LLC Submission history Latest submission status date: 2025-04-29 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription

Interaction Notes

  • No interaction notes stored yet.